Summary Endothelial receptor tyrosine kinases may play important roles in pathological vascular growth, particularly in tumours. In this study, immunohistochemistry was used to evaluate the expression of a novel endothelial receptor tyrosine kinase, Tie2/Tek, in the endothelium of vascular 'hotspots' in normal breast tissue (n = 10), benign breast lesions (n = 10) and in breast tumours (n = 123). Tie2 expression was detected in the endothelium of all breast tissues examined. However, the strongest expression of Tie-2 was seen in vascular 'hot spots' within the inflammatory infiltrate at the periphery of invasive tumours. Moreover, the proportion of Tie2-positive vessels (Tie2 counts/CD31 counts) was significantly higher in breast tumours than the proportion of Tie2-positive vessels in either normal breast tissue or benign breast lesions (P = 0.004 and 0.0001 respectively). These data are consistent with a role for Tie2 in tumour angiogenesis and demonstrate the potential use of Tie2 expression as a novel marker of the tumour vasculature.
It is now well established that the growth and development of solid tumours is tightly linked to the development of tumour vasculature (Craft et al, 1994; Hayes, 1994; Plate et al, 1994a; Folkman, 1995; Rak et al, 1995) . Consistent with this notion, a number of investigators have demonstrated that quantitative estimates of tumour vascularity are independent predictors of prognosis in a variety of solid tumours, most notably breast cancer (Weidner et al, 1991; Bosari et al, 1992; Horak et al, 1992; Toi et al, 1993) . Based on studies such as these, a tremendous effort is being made to understand the molecular mechanisms of tumour angiogenesis to provide the basis for the development of novel diagnostic and therapeutic agents.
Current evidence suggests that endothelial receptor tyrosine kinases that mediate the effects of known 'angiogenic' growth factors, such as VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) play crucial roles in physiological and pathological vascular growth (Dvorak et al, 1991; Kim et al, 1993; Craft et al, 1994; Hayes, 1994; Plate et al, 1994a and b; Senger et al, 1994; Brown et al, 1995; Folkman, 1995; Mustonen et al, 1995; Rak et al, 1995; Takahashi et al, 1995; Millauer et al, 1996) . Recently, a novel family of endothelium-specific receptor tyrosine kinases currently consisting of two members, Tiel and Tie2/Tek, has been shown to be essential for the normal development of the embryonic vasculature (Dumont et al, 1992;  Maisonpierre Partanen et al, 1992; Ziegler et al, 1992; Sato et al, 1993) . Disruption of Tiel function in transgenic mice led to fetal or early post-natal lethality characterized by diffuse vascular haemorrhage, suggesting a role for this receptor in Received 10 December 1996 Revised 28 May 1997 Accepted 24 June 1997 Correspondence to: KG Peters maintaining vascular integrity (Puri et al, 1995; Sato et al, 1995) .
Disrupting the function of Tie2, however, resulted in early embryonic lethality characterized by a defect in the formation of microvessels, supporting a role for Tie2 in developmental angiogenesis (Dumont et al, 1994; Sato et al, 1995) .
The requirement of Tiel and Tie2 function in the development of the embryonic vasculature has led to speculation that they may also play roles in normal and in pathological vascular growth in adulthood. Consistent with this notion, Tiel mRNA was upregulated in the endothelium of the neovasculature of healing skin wounds and in the endothelium of ovarian capillaries after hormone-induced superovulation . Moreover, Tiel expression has been shown to be up-regulated in the neovasculature of a variety of cancers, including brain, breast and melanoma, suggesting a role for Tiel in tumour angiogenesis (Kaipainen et al, 1994; Hatva et al, 1995; Salven et al, 1996) . Whether Tie2 might be up-regulated in tumour vessels has not been addressed. In the present study, a monoclonal antibody against the Tie2 extracellular domain was used to demonstrate the up-regulation of Tie2 expression in the pathological neovasculature of breast tumours.
MATERIALS AND METHODS Antibodies
A Tie2 murine monoclonal antibody was raised against purified, recombinant human Tie2 extracellular domain. Details regarding the production of this antibody will be described elsewhere (KG Peters and P Rao, in preparation). Briefly, a recombinant protein consisting of the entire human Tie2 extracellular domain fused at its C-tail with a 6His tag was produced in insect cells using a baculovirus expression system (Baculogold, Pharmingen). After purification by Ni+NTA agarose chromatography, this protein was 4°C, and 20,g of protein from HUVEC and HASMC cell lysate was resolved by 8% PAGE and then electrotransferred to nitrocellulose membrane and incubated with Ab33. Tie2 protein was visualized by incubation of the membrane with HRP-linked secondary antisera followed by treatment with enhanced chemiluminescence (ECI) reagent (Amersham).
Immunohistochemistry
For immunohistochemistry, randomly chosen specimens snapfrozen in OCT were obtained from archived material in the Duke University Cancer Center Tumor Bank. Tumour specimens were chosen to include about 50% node-positive and node-negative cases. These tissues included ten normal breast specimens (from reductive mammoplasties), ten benign lesions (fibroadenoma) and 123 tumours, the majority of which were invasive ductal carcinomas (Table 1) . Serial sections from each specimen were postfixed in acetone for 10 min, air dried and incubated for 50 min with either the Tie2 monoclonal antibody (Ab33) or the anti-CD31 monoclonal antibody. For negative controls, the primary antibody was deleted. Antigen antibody complexes were localized using a commercially available HRP-based detection system (Supersensitive, BioGenex).
Data analysis
To quantitate and compare Tie2 and CD3 1 expression, microvessels expressing either antigen were counted, as previously described for CD3 1 and other endothelial markers (Weidner et al, 1991; Horak et al, 1992) . Briefly, the most highly vascularized areas of each specimen were identified by scanning the CD3 1-stained sections at low power (x 40). Subsequently, individual microvessels expressing CD3 1 were counted in three different high-power fields (x 400). As the most prominent Tie2 staining colocalized with the most highly vascularized regions (by CD3 1 staining), Tie2 expression was quantitated by counting Tie2-positive microvessels in the same regions in which CD31 expression was determined. Microvessel number was quantitated by two different investigators (KP and AC) without consultation. Statistical analysis of the differences in overall tumour vascularity (CD31 count) and Tie2 expression (Tie2 count) were compared using t-tests.
RESULTS
To determine the expression pattern of Tie2 in breast tumours, a murine monoclonal antibody was raised against a recombinant extracellular domain of human Tie2 (see Materials and methods (Figure 1 ). In contrast, this band was not detected in lysates from smooth muscle cells. Thus, Ab33 recognized an endothelium-specific protein with a molecular mass consistent with the Tie2 receptor tyrosine kinase. Next, the expression of Tie2 was examined by immunohistochemistry with Ab33 in tissue samples of normal human breast tissue (n = 10), benign breast lesions (fibroadenoma; n = 10) and in breast tumours (n = 123) ( Table 1) . To correlate Tie2 expression with tumour vascularity, serial sections were stained in parallel Figure 3 Quantitation of Tie2 expression in normal breast tissue, benign breast lesions and in breast cancers. Density of microvessels and expression of Tie2 in 'vascular hot spots' were measured by counting vessels in 400 x high-power fields of sections stained for CD31 or Tie-2 respectively. A shows the comparison of Tie2 expression and B shows the comparison of vascularity among normal breast tissues, benign breast lesions and breast cancers. C compares the proportion of microvessels expressing Tie2 (expressed as the ratio of Tie2 to CD31 counts) in normal breast tissue, benign breast lesions and breast cancers with an anti-CD31 antibody (Horak et al, 1992; Toi et al, 1993) . In tumours, Tie2 was expressed most strongly in 'vascular hot spots', identified by CD3 1 staining as areas of clustering of microvessels ( Figure 2E-I) . Although vascular hot spots could often be detected in the substance of the tumour, Tie2 expression was most intense in areas of neovascularization at the tumour periphery, particularly in the interface between the tumour and the characteristic peritumoral inflammatory infiltrate (Figure 2J-M) .
British Journal of Cancer (1998) 77(1), [51] [52] [53] [54] [55] [56] . Figure 4 Comparison of inter-observer variability of Tie2 counts and CD31 counts. The Tie2 counts (A) and CD31 counts (B) of two independent observers were compared using linear regression analysis
In normal breast tissues, Tie2 was also expressed in vascular hot spots, although the intensity of staining was generally lower than that of Tie2 staining in tumours. In normal breast, hot spots were typically localized around ductal structures ( Figure 2C-D (Figure 2A-B) .
To quantitate expression of Tie2 in human breast tissues, vascular hot spots were localized by low-power examination of the stained tissue specimen, and the number of Tie2-positive vessels was counted in individual high-power fields (x 400). Using this approach, the number of Tie2-positive vessels in vascular hot spots was significantly higher in tumours than in benign lesions or normal breast tissue ( Figure 3A) . Quantitation of CD3 1-positive vessels yielded similar results ( Figure 3B) . Similarly, vascular hot spots in breast tumours had a significantly higher proportion of Tie2-positive vessels (Tie2/CD3 1) than did benign breast lesions or normal breast tissue ( Figure 2C ). Despite the increased expression of Tie2 in tumours, there was no statistically significant correlation between Tie2 counts and tumour size, tumour grade or lymph node status. Attesting to the reliability of counting Tie2-positive vessels, the inter-observer variability of Tie2 counts ( Figure 4A ) was similar to the inter-observer variability of counting CD3 1-positive vessels ( Figure 4B ). (Weidner et al, 1991; Bosari et al, 1992; Horak et al, 1992; Weidner et al, 1992; Fox et al, 1993 Fox et al, , 1994 Toi et al, 1993; Gasparini et al, 1994; Heimann et al, 1996) , our study and other studies have not been able to confirm these findings (Van Hoef et al, 1993; Axelsson et al, 1995; Goulding et al, 1995; Siitonen et al, 1995) . There are at least two potential explanations for these disparate results. First, immunostaining using endothelial markers, such as antibodies against factor VIII-related antigen, CD34 and CD3 1, may be difficult to reproduce because of limitations of available methodology for immunohistochemistry or, alternatively, because of differences in the methodology for selecting and quantitating vascular hot spots (Van Hoef et al, 1993; Goulding et al, 1995) . Second, it is possible that simply quantitating the vascularity of individual tumours may not always correlate with the ability of the tumour to promote vascular growth. For example, it is likely that some tumours, although highly vascular, have extremely limited abilities to induce new vascular growth and thus may not differ prognostically from poorly vascularized tumours with the same low propensity to mediate new vessel growth.
DISCUSSION
Despite these disparate results, it seems likely that analysis of the tumour vasculature will yield important prognostic and therapeutic information. For example, endothelial antigens that are upregulated during angiogenesis, such as VEGF receptors, have already shown promise as markers of tumour endothelium in small numbers of patients (Kaipainen et al, 1994; Senger et al, 1994; Brown et al, 1995; Easty et al, 1995; Hatva et al, 1995; Rak et al, 1995; Takahashi et al, 1995 Salven and colleagues (1996) who found that despite the upregulation of Tiel in breast cancers compared with normal breast tissue, there was no statistically significant correlation between Tie 1 expression and several prognostic indicators. As the proposed role of the Tie family of receptors is in the maturation and stabilization of nascent vessels, it is tempting to speculate that they might not provide the earliest and therefore most sensitive markers of newly formed vessels Dumont et al, 1994; Puri et al, 1995; Sato et al, 1995; Folkman et al, 1996; Suri et al, 1996; Vikkula et al, 1996) . Vascular endothelial growth factor is currently a leading candidate for an endogenous mediator of tumour angiogenesis. VEGF and VEGF receptors are expressed in the endothelium of a variety of different tumours, and blocking VEGF receptors inhibit the growth of a number of murine tumours and human tumour xenografts (Dvorak et al, 1991; Millauer et al, 1994; Plate et al, 1994b; Senger et al, 1994; Brown et al, 1995; Easty et al, 1995; Takahashi et al, 1995; Borgstrom et al, 1996) . However, a recent study showed that different murine mammary tumours had variable responses after blockade of the VEGF pathway. Importantly, tumours that did not respond well to VEGF blockade expressed Tie2, suggesting that Tie2 could provide an alternative pathway for tumour angiogenesis (Millauer et al, 1996) . Taken together with the results of the present study, these results are consistent with a role for Tie2 in tumour angiogenesis and suggest that therapeutic approaches targeting the Tie2 pathway should be further explored. Considering this possibility, using a battery of endothelial markers may provide the best information for use both to determine prognosis and perhaps to guide anti-angiogenic therapy.
